ReviewCancers2025
Rising Trends in Prostate Cancer Among Asian Men: Global Concerns and Diagnostic Solutions.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan.Advances in therapy · 2026Article
- Burden and Trends of Genitourinary Cancers Across the Americas: A GBD 2023 Analysis of Regional Socioeconomic Gradients.Cancers · 2026Article
- Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms.Drugs in R&D · 2026Article
- Breath Aldehyde Profiling using PFBHA-GC/MS as a Prostate Cancer Biomarker.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- MiR-135a-3p inhibits the progression of prostate cancer by targeting TLR4.Cancer biology & therapy · 2025Article
- EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study.Cancers · 2025Article
- Paradigm Lost.Cancers · 2025Article
- Occurrence and Impact of Intraoperative Anastomotic Leakage in Retzius-Sparing Robot-Assisted Radical Prostatectomy.Medicina (Kaunas, Lithuania) · 2025Article
- PSMA-based theranostics in diagnosing and treating prostate cancer in the Asian male population: a narrative review.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Asia comprises 60% of the global male population, yet Asian men's health issues, such as prostate cancer, remain sparse in the literature. Clinical researchers have often overlooked prostate cancer in Asian men, as available statistics suggest that Asian men are less likely to develop prostate cancer compared to Caucasian, Black, and Hispanic males. However, cultural investigations have indicated these figures may be influenced by factors such as cultural taboos, superstition and misconception, limited access to diagnostic tools and healthcare facilities, and epidemiological factors in terms of lifestyle, environmental exposure, and genetics. In particular, the lack of diagnostic resources, coupled with cultural stigmas surrounding cancers affecting the genitalia in Asian societies, may contribute to significant underreporting. Rapid aging population growth in East Asia and the continuing shift in Asiatic lifestyles towards Westernization will likely contribute to a continued rise in prostate cancer incidence among Asian men in the coming years. A comprehensive review of novel and commercially available prostate cancer detection tests demonstrates that accurate, less-invasive tools could relieve many of the pressures surrounding Asian men and their prostate health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.